Literature DB >> 12635175

Second cancers in survivors of childhood cancer.

Smita Bhatia1, Charles Sklar.   

Abstract

More than 70% of children diagnosed with cancer can now be expected to be long-term survivors. However, the consequences of 'cure' might be considerable for the survivors of cancer: 60-70% of young adults who have survived childhood cancer will develop at least one medical disability as a result of their cancer or, more commonly, as a result of their therapy. Of these, the most devastating is a second cancer.

Entities:  

Mesh:

Year:  2002        PMID: 12635175     DOI: 10.1038/nrc722

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  61 in total

1.  Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Authors:  Jean L Nakamura; Connie Phong; Emile Pinarbasi; Scott C Kogan; Scott Vandenberg; Andrew E Horvai; Bruce A Faddegon; Dorothea Fiedler; Kevan Shokat; Benjamin T Houseman; Richard Chao; Russell O Pieper; Kevin Shannon
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

Review 2.  Collaborative Research in Childhood Cancer Survivorship: The Current Landscape.

Authors:  Smita Bhatia; Saro H Armenian; Gregory T Armstrong; Eline van Dulmen-den Broeder; Michael M Hawkins; Leontien C M Kremer; Claudia E Kuehni; Jørgen H Olsen; Leslie L Robison; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

3.  A Novel Locus Predicts Spermatogenic Recovery among Childhood Cancer Survivors Exposed to Alkylating Agents.

Authors:  Yadav Sapkota; Carmen L Wilson; Asifa K Zaidi; Wonjong Moon; Klementina Fon Tacer; Lu Lu; Qi Liu; Jessica Baedke; Rikeenkumar Dhaduk; Zhaoming Wang; Wassim Chemaitilly; Matthew J Krasin; Fred B Berry; Jinghui Zhang; Melissa M Hudson; Leslie L Robison; Daniel M Green; Yutaka Yasui
Journal:  Cancer Res       Date:  2020-06-17       Impact factor: 12.701

4.  Incidence of multiple primary malignancies among patients with bone cancers in Sweden.

Authors:  Jianguang Ji; Kari Hemminki
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-17       Impact factor: 4.553

5.  Second gastric cancers among patients with primary sporadic and familial cancers in Sweden.

Authors:  J Ji; K Hemminki
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

Review 6.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

Review 7.  Childhood cancer survivorship: an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects.

Authors:  Saro H Armenian; Leslie L Robison
Journal:  Curr Opin Pediatr       Date:  2013-02       Impact factor: 2.856

8.  Synchronous and antecedent nonthyroidal malignancies in patients with papillary thyroid carcinoma.

Authors:  Sara E Murray; David F Schneider; Philip S Bauer; Rebecca S Sippel; Herbert Chen
Journal:  J Am Coll Surg       Date:  2013-03-20       Impact factor: 6.113

9.  Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.

Authors:  Grace Choi; Brian Huang; Emile Pinarbasi; Steve E Braunstein; Andrew E Horvai; Scott Kogan; Smita Bhatia; Bruce Faddegon; Jean L Nakamura
Journal:  Cancer Res       Date:  2012-10-15       Impact factor: 12.701

10.  An extra copy of p53 suppresses development of spontaneous Kras-driven but not radiation-induced cancer.

Authors:  Everett J Moding; Hooney D Min; Katherine D Castle; Moiez Ali; Loretta Woodlief; Nerissa Williams; Yan Ma; Yongbaek Kim; Chang-Lung Lee; David G Kirsch
Journal:  JCI Insight       Date:  2016-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.